Skip to content
PoliticalRepoPoliticalRepo

Subjects · US

Healthcare

Records whose title is actually about this topic. Use a country filter if the list is still too broad.

251 records in US in 2026

All countriesSearch this topic

Records

Bill· HRH.R. 9559 (119th)referred

IBOGAINE Act

United States · United States Congress · 30 June 2026

Bill· HRH.R. 9515 (119th)referred

MFA Act

United States · United States Congress · 29 June 2026

Bill· HRH.R. 9504 (119th)reported

Tax Exempt Hospital Transparency Act

United States · United States Congress · 29 June 2026

Tax Exempt Hospital Transparency Act This bill requires tax-exempt hospital organizations to report additional information to the Internal Revenue Service. The bill defines a tax-exempt hospital organization as an organization that is licensed or recognized as a hospital and is required to conduct a community health needs assessment and adopt a strategy to meet the needs identified in the assessment, have a written financial assistance policy, limit charges for emergency and medically necessary care provided to individuals eligible for financial assistance and prohibit the use of gross charges, meet certain billing and collection requirements, and file IRS Form 990 (Return of Organization Exempt From Income Tax). Under the bill, a tax-exempt hospital organization must include with Form 990 certain identifying information and a description of how the organization addresses the needs identified in the most recent community health needs assessment, the needs not addressed, and the reasons why needs are not being addressed; audited financial statements; the value (at cost) of the financial assistance provided; and the numbers of completed financial assistance applications received, granted, and denied during the tax year. Further information reporting requirements are imposed on certain large or high-revenue tax-exempt hospital organizations. Finally, the bill requires the Government Accountability Office to (1) study and report the costs associated with the additional information reporting requirements, and (2) estimate the amount of tax revenue that would be generated from the 25 tax-exempt hospital organizations with the highest gross revenue if such organizations were not exempt from tax.

Bill· HRH.R. 9468 (119th)reported

STAR Act

United States · United States Congress · 25 June 2026

Bill· HRH.R. 9455 (119th)referred

SMOOTH Payments Act

United States · United States Congress · 25 June 2026

Bill· HRH.R. 9488 (119th)referred

Health Disparity Zones Act of 2026

United States · United States Congress · 25 June 2026

Health Disparity Zones Act of 2026 This bill provides for the designation of Health Disparity Zones in certain geographic areas with documented and measurable health disparities. This designation, which expires 10 fiscal years after the bill's enactment, confers eligibility for certain grants, student loan repayment programs, and tax credits for those working to reduce health disparities and improve health outcomes in these zones. Specifically, community-based nonprofits or local government agencies, in coalition with health care providers, social service organizations, and others, may apply to the Department of Health and Human Services (HHS) for the designation. The application must include a plan to reduce health disparities and achieve other outcomes. In implementing the program, HHS must consult with, among others, the Department of Housing and Urban Development. When approving applications, HHS shall consider factors including geographic diversity and the commitment of supporting funds from the private sector. HHS (1) may award grants to organizations or agencies that applied for the designation to support activities aligned with their plans, and (2) must carry out a student loan repayment program for health care providers who agree to provide services in a Health Disparity Zone. In addition, the bill establishes tax credits for employers that hire, and individuals who work as, Health Disparity Zone workers.

Bill· SS. 4913 (119th)referred

MOMMIES Act

United States · United States Congress · 24 June 2026

Maximizing Outcomes for Moms through Medicaid Improvement and Enhancement of Services Act or the MOMMIES Act This bill establishes a series of programs and requirements under Medicaid and the Children's Health Insurance Program (CHIP) relating to maternal health. For example, the bill expands eligibility for coverage under Medicaid and CHIP from 60 days to one year after the last day of pregnancy and requires such coverage to include oral health services. The bill also establishes a demonstration program in which states receive grants to implement or expand models for maternity care homes that provide services to Medicaid or CHIP beneficiaries. The Government Accountability Office must report on (1) gaps in coverage under Medicaid and CHIP for pregnant and postpartum women, and (2) the use of telehealth by state Medicaid programs to increase access to maternity care.

Bill· SJRESS.J.Res. 198 (119th)failed

A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".

United States · United States Congress · 24 June 2026

This joint resolution prohibits the Centers for Medicare & Medicaid Services (CMS) from testing a new Medicare payment model in certain states that involves a prior authorization process and the use of enhanced technology by third-party contractors to determine whether certain claims should be paid. Specifically, the joint resolution nullifies a notice issued by the CMS on July 1, 2025, titled Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model . (On May 12, 2026, the Government Accountability Office issued a letter of opinion stating that this notice constituted an agency rule and is therefore subject to the Congressional Review Act.) The CMS selected six states to participate in this model over a six-year period: New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington. Under the model, contracted companies must process prior authorization requests (i.e., requests for coverage determinations before a service is furnished) for certain services using enhanced technology (e.g., artificial intelligence). Contracted companies are paid based on the share of resulting savings. The CMS aims to test the model's ability to produce accurate results while streamlining the prior authorization process for Medicare claims. The model is based in part on similar processes used for Medicare Advantage claims.  CMS began implementing the model on January 1, 2026. This joint resolution prohibits the CMS from continuing to do so.

Bill· SS. 4895 (119th)referred

Turn the Tide Act

United States · United States Congress · 24 June 2026

Bill· SS. 4939 (119th)referred

Countering CCP Act

United States · United States Congress · 24 June 2026

Bill· SS. 4888 (119th)referred

PREVENT Act

United States · United States Congress · 24 June 2026

Bill· HRH.R. 9418 (119th)referred

Access to Innovative Treatments Act of 2026

United States · United States Congress · 24 June 2026

Access to Innovative Treatments Act of 2026 This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so. Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do not apply if the CMS already conducted such a review within a two-year period. The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.

PreviousPage 5 of 6Next